Abstract: Abstract: Abstract: Abstract: Patients with multiple myeloma (MM) treated with conventional chemotherapy have an average survival of approximately three years. High dose chemotherapy followed by autologous stem cell transplantation (ASCT), first introduced in the mid-1980s, is now considered the standard therapy for almost all patients with multiple myeloma, because it prolongs overall survival and disease free survival. Between November 1997 and October 2006, 122 patients with MM (58 females, 64 males, median age 51.0 years [± 7.98] range: 30-66 years) were transplanted in the Department of Hematooncology and Bone Marrow Transplantation at the Medical University of Lublin: 47 patients were in complete remission or in unconfirmed complete remission, 66 patients were in partial remission, and nine had stable disease. Of these, there were 95 patients with IgG myeloma, 16 with IgA myeloma, one with IgG/IgA, one with IgM myeloma, five with non secretory type, two with solitary tumor and two with LCD myeloma. According to Durie-Salmon, 62 patients had stage III of the disease, 46 had stage II and four had stage I. Most patients (69/122) were transplanted after two or more cycles of chemotherapy, 48 patients were transplanted after one cycle of chemotherapy, one patient after surgery and rtg--therapy and four patients had not been treated. In mobilisation procedure, the patients received a single infusion of cyclophosphamide (4-6 g/m 2 ) or etoposide 1.6 g/m 2 followed by daily administration of G-CSF until the peripheral stem cells harvest. The number of median harvest sessions was 2.0 (± 0.89) (range: 1-5). An average of 7.09 (± 33.28) × 10 6 CD34 + cells/kg were collected from each patient (range: 1.8-111.0 × 10 6 /kg). Conditioning regimen consisted of high dose melphalan 60-210 mg/m 2 without TBI. An average of 3.04 (± 11.59) × 10 6 CD34 + cells/kg were transplanted to each patient. Fatal complications occured in four patients (treatment--related mortality = 3.2%). In all patients there was regeneration of hematopoiesis. The median number of days for recovery to ANC > 0.5 × 10 9 /l was 13 (± 4.69) (range: 10-38) and platelets recovery to > 50 × 10 9 /l was 25 days (± 11.65) (range: 12-45). Median time of hospitalization was 22 days (± 7.14) (range: 14-50). Patients were evaluated on day 100 after transplantation: 74.9% achieved CR and nCR, 14.3% were in PR, 5.4% had SD and 5.4% had progressed. Median of OS was 45 months (± 30.67). OS at 3-years was 84% and at 7-years 59%. Median PFS was 25 months (± 26.13). PFS at 3-years was 68%, and at 7-years was 43%. At present (November 2009) 52 patients (42%) are still alive. High-dose chemotherapy followed by autologous stem cell transplantation is a valuable, well tolerated method of treatment for patients with MM that allows the achievement of long--lasting survival.
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The clinical course of transplantation is summarized in Table 2 , and the results of ASCT are shown in Table 3 .
Discussion
Discussion Discussion Discussion Discussion MM is characterized by a marked resistance to conventional chemotherapy. It has been shown that drug resistance can be overcome by dose escalation [5] [6] [7] . High-dose therapy with MEL was introduced in the mid-1980s [8] . The IFM randomized trial first demonstrated the superiority of high-dose therapy supported by autologous bone marrow transplantation compared to conventional chemotherapy, with OS at 7-years of 43% vs. 27% (p < 0.03) and EFS at 7-years of 16% vs. 8% (p < 0.01) [2] . Five more trials were performed to compare ASCT versus conventional chemotherapy, and whereas three of them showed no benefit in terms of EFS or OS [9] [10] [11] , the other two confirmed the benefit, with median OS of 54 months and OS at 3-years of 77% [12, 13] .
Many factors can be responsible for ASCT outcome, including biological and individual factors before transplantation, genetic factors, biological parameters, b2-microglobulin and albumin levels forming International Staging System, sensitivity to initial chemotherapy, and proliferative index [14, 15] . CR status before ASCT has been revealed to be the most important factor contributing to a long-lasting response and prolonged survival in patients with MM [16, 17] . Sensitivity to initial chemotherapy measured by the M-protein type at time of transplant is the most reliable predictor of CR after ASCT [16, 17] . A recent meta-analysis carried out by Van de Velde et al. also confirmed the strong association between maximal response to induction therapy and longterm outcome after ASCT [18] . The chromosomal abnormalities del(13), t(4,14) and del(17p) have been associated with a shorter survival after ASCT and have become a marked risk factor for all MM patients [19] .
Novel agents (i.e. thalidomide, lenalidomide and bortezomib) have been introduced. They have an increased anti-myeloma effect and prolong survival due to better results of initial therapy before ASCT and/ /or more effective rescue regimens for patients with relapsed/refractory disease.
Thalidomide-based regimens as initial therapy in multiple myeloma: TD (thalidomide + dexamethasone); TAD (thalidomide + dexamethasone + adriamycin); and CTD (cyclo-phosphamide + thalidomide + dexamethasone) have resulted in raising the response rate (RR) -72% to 87% and CR rate up to 19% before ASCT. After transplantation, RR rate increased to 88%, including CR and nCR rates up to 51% [20, 21] .
Lenalidomide-based therapy was applied in MM patients in two trials conducted by ECOG and SWOG with RR 82% and 85% respectively and CR rate 4% and 22% before transplantation, with OS at 4-years 92% after ASCT [22] .
Bortezomib in combination with thalidomide or lenalidomide or anthracyclins or dexamethasone boosted RR from 60% to 95%, with 10% to 44% CRs. In all these pilot studies, the CR markedly increased after transplantation (31-57%) [3, 4] .
During the nine years of this study, 122 patients with multiple myeloma were transplanted in the Department of Hematooncology and Bone Marrow Transplantation in Lublin. Different regimens before ASCT were applied: VAD, EDAP, VMBCP, CTD, T T T T Table 2 Figure 1 . Figure 1 . Figure 1 . Figure 1 . [23, 24] . Autologous stem cell transplantation does not cure the condition. Most patients will relapse within a median of three years. It has been suggested that double transplantation could be more effective than single transplantation to cure patients with multiple myeloma or to prevent relapse. The IFM 94 study compared single versus double ASCT among 399 patients and showed no benefit of double ASCT: at 7-years OS was 21% and EFS 20%. This trial confirmed the benefit of double ASCT only in patients who failed to achieve a very good partial response after the first transplantation [25] . Four further trials comparing single versus double transplantation were conducted, and two of them reported a survival benefit in favour of tandem transplantation [10, [26] [27] [28] .
In 25 patients, tandem transplantation was performed in our centre. OS was median 83 months (± 32.35), mean 75.57 months and PFS was 45 months (± 30.73), mean 47.38 months. They reached OS at 7-years 73%, compared to OS 59% in once transplanted patients and EFS 67% vs. 43% respectively. But in longer observation (ten years) there were no significant differences observed in OS and EFS when comparing single versus double transplantation.
Maintenance therapy after ASCT has been applied for many years in MM patients. First, interferon alpha prolonged PFS and OS by between 4 and 8 months [29] . The IFM group and the Australian group showed that maintenance therapy with thalidomide prolonged duration of PFS and OS after ASCT [30, 31] . In the IFM trial, OS at 4-years was 87% and PFS at 3-years was 52%. In the Australian group, OS at 3-years was 86% and PFS at 3-years was 42%. Today, thalidomide is recommended as a maintenance therapy for less than 12 months and for patients who do not achieve CR after ASCT. Lenalidomide is now considered as the ideal maintenance drug, but clinical trials are still ongoing. We used routine maintenance therapy with thalidomide at a dose of 100 mg daily or interferon alpha at a dose of 3 mln U/three times weekly in cases where CR or nCR after ASCT was not obtained. These therapies were applied until progression and were well tolerated. Figure 3 . Figure 3 . Figure 3 . Figure 3 . 
